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Abstract
Purpose: To customize clinical practice guidelines (CPGs) for cataract management in the Iranian population.
Methods: First, four CPGs (American Academy of Ophthalmology 2006 and 2011, Royal College of 
Ophthalmologists 2010, and Canadian Ophthalmological Society 2008) were selected from a number of 
available CPGs in the literature for cataract management. All recommendations of these guidelines, together 
with their references, were studied. Each recommendation was summarized in 4 tables. The first table 
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INTRODUCTION
Cataract is the progressive deterioration of optical 
qualities of the crystalline lens.[1,2] The most common 
form is age‑related cataract which affects a high 
percentage of people over the age of 50 years.[2] 
Cataract has been reported to be the cause of 47.8% 
of all cases of blindness worldwide and are a serious 
health issue particularly in developing countries.[3] In 
Iran, cataract is are highly prevalent, and based on two 
studies performed on Tehran citizens over 40 years, 
a prevalence of 12% to 19.1% has been reported.[4,5] 
Another study from Varamin district has reported 
cataract as the cause of blindness in 31.7% of cases and 
severe visual acuity impairment in 47.5% of cases.[6] 
Currently, the only option for visual rehabilitation in 
human subjects with cataract is surgical removal of 
the lens,[7] which is one of the most successful surgical 
treatments.[2] This surgery has vastly changed during 
the past 20 years,[8] and with advances in microscopic 
surgery and intraocular lens (IOL) manufacturing, 
the quality of vision after surgery has dramatically 
improved, leading to more cases of surgical treatment 
being performed.[9]
National clinical practice guidelines (CPGs) include 
clinical recommendations based on systematically 
verified evidence. These guidelines are developed to 
evaluate the effectiveness, safety, and efficiency of 
inventions considering domestic factors and justly 
distributed health care. These guidelines have an impact 
on decision‑making by both clinicians and health care 
authorities.[10,11]
The present guideline for management of cataract in 
adult patients has been customized in order to comply 
with guidelines of the Fifth National Development 
Program of the Islamic Republic of Iran, particularly 
section D of the 32nd amendment calling for customizing 
national CPGs for the healthcare system and providing 
fair access to continuous and qualified health care as 
one of the main goals of the health care system. We also 
stressed adhering to the 75th strategic goal of the Iranian 
Ministry of Health and Medical Education regarding 
use of national medical guidelines and establishment of 
evidence‑based practices. This guideline was customized 
in the Ophthalmic Knowledge Management Unit (KMU) 
at Shahid Beheshti University of Medical Sciences in 2011 
to fulfill requirements by the Iranian Ministry of Health 
and Medical Education.[12,13]
Iranian cataract management guidelines contain 
80 clinical recommendations with the aim of 
standardizing and customizing different aspects of 
cataract management in adults including etiology, 
progression, indication for intervention, diagnosis, 
treatment, and pre‑and post‑surgical care.
METHODS
A group including general ophthalmologists as well 
as cornea, vitreoretinal and strabismus subspecialists, 
masters of optometry and biostatistics, expert searcher, 
head of the Office for healthcare standards, Deputy of 
Curative Affairs, Iran Ministry of Health and Medical 
Education representative participated in this effort.
Search for Related Guidelines and Screen 
Extracted Guidelines
First, medical data resources including National 
Guideline Clearinghouse, Guidelines International 
Network, National Institute for Clinical Excellence, 
Scott ish Intercollegiate Guidelines Network, 
National Health and Medical Research Council, and 
New Zealand Guidelines Group were searched to find 
national guidelines related to our subject. All guidelines 
were evaluated based on their quality characteristics 
such as structural soundness, availability of the full 
guideline, and being up‑to‑date. In the next step, 
guidelines which fulfilled all of the above‑mentioned 
showed the recommendation itself in clinical question components format along with its level of evidence. 
The second table contained structured abstracts of supporting articles related to the clinical question with their 
levels of evidence. The third table included the customized recommendation of the internal group respecting 
its clinical advantage, cost, and complications. In the fourth table, the internal group their recommendations 
from 1 to 9 based on the customizing capability of the recommendation (applicability, acceptability, external 
validity). Finally, customized recommendations were sent one month prior to a consensus session to faculty 
members of all universities across the country asking for their comments on recommendations.
Results: The agreed recommendations were accepted as conclusive while those with no agreement 
were discussed at the consensus session. Finally, all customized recommendations were codified as 80 
recommendations along with their sources and levels of evidence for the Iranian population.
Conclusion: Customization of CPGs for management of adult cataract for the Iranian population seems to 
be useful for standardization of referral, diagnosis and treatment of patients.
Keywords: Adult; Cataract; Iran; Practice Guideline
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requirements were scored by using AGREE instrument. 
This evaluation instrument included 23 questions 
covering different aspects of the guideline, and the 
guidelines were given a score of 0 to 100. Finally, based 
on their scores, the guidelines from the American 
Academy of Ophthalmology (2006 and 2011),[2,14] 
the Royal College of Ophthalmologists,[9] and the 
Canadian Ophthalmological Society[1] with total scores 
of 85, 81, 80, and 75, respectively, were selected as 
reference guidelines.
The Process of Evaluating the Selected 
Clinical Guidelines
We first designed the questions based on the selected 
CPGs, then categorized them according to their 
precedence in the treatment process of cataract [Table 1].
Evaluating the content of referenced guidelines
The recommendations of the selected guidelines 
which have addressed each question were included 
in Table 2. Those recommendations which had similar 
populations or interventions were placed in the same 
table. To fill this table, we first recorded four parts of 
questions which included the patient population or the 
disease (P), intervention or exposure (I), comparison (C), 
and finally, outcome (O), and then entered the main 
related recommendation. We also entered technical 
breakthroughs if suggested by reliable scientific 
organizations or countries as new recommendations.
Organizing the recommendations in tables helped us 
recognize different aspects of the final guideline. This 
method also optimized the search for related evidence.
Analysis of the evidence supporting each recommendation
Abstracts of all supporting evidence for each 
recommendation were extracted. We also searched the 
Coherence Library, Trip Database (Evidence‑based 
synopses), Bandolier, and PubMed (Clinical queries 
section) databases from 2007 to 2012 for the clinical 
questions related to each suggested recommendation. 
These databases are known as reliable sources for 
information with highest levels of evidence based on 
systematic review, meta‑analysis, and clinical trial studies. 
All these abstracts were criticised by our team, and their 
related details were entered in Table 3. If there was any 
ambiguity in the abstract, the full text was studied.
The level of evidences have been determined based on 
Tables 4 and 5. If there was more than one recommendation 
for a clinical question and those recommendations did not 
have the same level of evidence, the recommendation 
with a higher level of evidence was selected.
Analysis of the clinical advantage of recommendations
After completing the supporting evidence and choosing 
the recommendation with the highest level of evidence, 
the related recommendation was entered in Table 6. 
Next, the internal group evaluated the recommendation 
in terms of its benefits, side effects, and treatment cost.
The benefit of an intervention is different from its 
outcome. It includes the ability to manage the treatment 
at lower levels of the health care system, at specialty 
and subspecialty levels, decrease admission rate and 
duration, decreased the need for surgical treatment, 
increase patient satisfaction, allow faster recovery, 
reduce the need for post‑treatment visits, and minimize 
patient pain and suffering.
We also categorized side effects based on their nature 
and severity as well as the effectiveness based on the 
supporting evidences.
Table 1. Algorithm of the clinical practice guidelines
Cataract management
Nonsurgical (risk factors for cataract progression)
Surgical
Preoperative
Indication (VA, other conditions)
Assessment (eye, laboratory, intraocular lens)
Risk factors for cataract operation
Intraoperative
Anesthesia, operational stages
Postoperative
Follow‑up, complications
VA, visual acuity
Table 2. Analysis of recommendation
Question P I 
(E)
C O Question 
type
Reference 
guidelines
Phrase of 
recommendation
Level  
of 
evidence
Inconsistency of 
recommendations
Technical 
breakthrough
New  
systematic 
review
New 
studies
G1
G2
G3
G4
P, patient or population; I, intervention; E, exposure; C, comparison; O, outcome; G1, Cataract in the Adult Eye PPP‑American Academy of 
Ophthalmology‑2011; G2, Cataract surgery guidelines‑The Royal College of Ophthalmologist‑2010; G3, Canadian Ophthalmological Society 
evidence‑based clinical practice guidelines for cataract surgery in the adult eye‑2008; G4, Cataract in Adult eye‑American Academy of 
Ophthalmology‑Revised 2006
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Finally, our team, as an internal reviewer, gave low, 
moderate, or high scores to the clinical advantages of 
each recommendation.
Customizing the recommendations
Customization of each recommendation was evaluated 
in Table 7. In this table, the applicability, external 
validity, and acceptability of each recommendation was 
determined, and each recommendation was given a score 
of low,[1‑3] moderate,[4‑6] or high.[7‑9]
Consensus Process
First consensus (External peer review)
All customized recommendations and related 
data [Tables 2, 3, 6, and 7] were sent to expert in the 
field of cataract surgery at different public hospitals 
supervised by medical universities (Tabriz University of 
Medical Sciences, Shahid Beheshti University of Medical 
Sciences, Iran University of Medical Sciences, Tehran 
University of Medical Sciences, Ahvaz Jundishapur 
University of Medical Sciences, Zahedan University of 
Medical Sciences, and Mashhad University of Medical 
Sciences) after removing the internal scores.
Participants were asked to:
• Evaluate the recommendations and determine the 
clinical advantage score, customized potential score, 
and total score for each recommendation
• Add any evidence related to recommendations that 
were not included in our search, which could change 
the final decision, if possible.
Evaluation of total scores
After collecting the external peer review scores, 
agreement among the external peer review was assessed 
by our team, and the agreed recommendations were 
considered as final customized recommendations.
Second consensus
The external and internal reviewers gathered again and 
discussed non‑agreed recommendations, some of which 
were modified and rescored to achieve agreement from 
both groups.
Final Assessment of Recommendations
All recommendation were re‑evaluated by our team, and 
the final recommendations were recorded in a file with 
special codes in abbreviations, which included the name 
of the adopted CPG [Table 8], its level of evidence, and the 
number for its reference. For example (C4), (I), indicates that 
the recommendation has stemmed from recommendation 
number 4 from the Canadian Ophthalmological Society 
clinical practice guidelines for adult cataract surgery, a 
Clinical Practice Guideline with level of evidence of I.
RESULTS
The result of customizing 4 prior guidelines for the 
Iranian population may be summarized into the 80 
recommendations classified below.
Non‑surgical Treatments/Risk Factors for 
Cataract Progression
1. It is recommended that ophthalmologists suggest 
that patients use sunglasses and hats with visors to 
reduce sun ray (UV‑B) damage and progression of 
cortical cataracts.[15‑17] (I), (A1,2)
2. Based on a high level of evidence, supplements such 
as antioxidants, Vit C, Vit E, Vit A and beta‑carotene 
do not prevent or reduce the rate of progression of 
cataracts.[18‑20] (I), (A1,2)
3. Considering the proven effect of quitting cigarette 
smoking in limiting the progression of cataracts, it is 
recommended that ophthalmologists ask all patients 
with lens opacity to quit smoking.[21‑25] (I), (A1,2, R 3‑3)
4. It is recommended to inform patients about the 
Table 3. Analysis of evidences
Code Population Intervention Comparison Primary 
outcomes
Effect 
size
Statistical 
value
Level of 
recommendation
Table 4. Level of evidence
Level of evidence Type of evidence
I Randomized clinical trials
Systematic reviews
Meta‑analysis
II Controlled clinical study without 
randomization at least one
Well‑designed cohort study
Well‑designed case control
Cross sectional study
III Surveys, descriptive, case series studies
IV Experts opinion, consensus
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progression of the condition, but aspirin and thiazides 
do not have a role in this respect. Discontinuation 
of cataract‑causing drugs may be recommended by 
physicians, if possible.[28,29] (I), (A1)
6. It is recommended that the increased risk of cataract 
be discussed with diabetic patients[30‑32] (II), (A1)
7. It is recommended that the increased risk of accidents 
and bone fractures be discussed with patients 
who have cataracts but do not wish to be operated 
on.[33‑37] (I), (C4).
Surgical Treatments/Preoperative/Indication 
of Cataract Surgery Based on Visual Acuity
8. If cataract is the main and primary cause of visual 
loss, surgery is indicated. (IV), (consensus C19)
9. Cataract surgery is recommended when vision loss 
is not corrected with non‑surgical methods meet 
patients’ needs.[38,39] (IV), (A22, C2)
10. It is recommended that in evaluating cataracts and 
determining the time of surgery, with the exception 
of visual acuity, other factors such as need for far 
sight, near sight, and sight under different lighting 
conditions be considered.[40‑45] (I), (A1)
11. In patients who have less than standard visual acuity 
according to their occupation (like drivers, soldiers, 
and pilots) and wish to continue their occupation, 
cataract surgery is indicated even when there are 
not many functional deficits under normal life 
circumstances. (IV), (consensus C3).
Surgical Treatments/Preoperative/Indication 
for Fellow Eye Cataract Surgery
12. Indication for surgery on the second eye is the same 
as the first eye, but in some cases of anisometropia, 
earlier operation is recommended. The time between 
surgeries should be long enough for detecting 
possible complications of the first procedure 
increased risk of cataracts after long‑term use of 
oral or inhaled steroids, and alternative medications 
should be used, if possible.[26,27] (II), (A1)
5. The use of steroids, amitriptyline, statins, anti‑diabetes 
pills, insulin, and potassium‑sparing diuretics 
increase the risk of cataracts and cause faster 
Table 6. Clinical advantages of recommendations
Question Phrase of 
recommendation
Level of 
evidence
Costs Clinical advantages of the 
recommendations
Clinical advantages 
score
Benefits Effect size Side 
effects
Low Moderate High
Low: Score 1‑3; Moderate: Score 4‑6; High: Score 7‑10
Table 7. Adaptability of the recommendation
Question P I C O Type of the 
question
Phrase of 
recommendation
Adaptability of the recommendation Adaptation 
score
Total 
scoreApplicability Acceptability External 
validity
Low Low
Moderate Moderate
High High
P, patient or population; I, intervention; C, comparison; O, primary outcomes; Low: Score 1‑3; Moderate: Score 4‑6; High: Score 7‑9
Table 5. Level of evidence according to the type of study
Level of evidence Type of the study
Therapy (RX)
I SR, RCT
II CT, cohort
III Case control, cross sectional, 
case series
IV Opinion
Etiology/harm (risk factor)
I RCT, cohort
II Case control
III Description studies, Survey
IV Opinion
Diagnosis (DX)
I SR CPR*, cross sectional
II Cohort
III Case control
IV Opinion
Prognosis (PX)
I Inception cohort**
II Prospective cohort
III Historical cohort, case control
IV Opinion
*Clinical prediction rules, these studies are designed to evaluate 
the combination effect of different clinical variables for diagnosis 
or prognosis of the disease and include two steps: first, estimation 
of the relationship of the variables and the second, validation; 
**Inception cohort study, a type of cohort study in which the time 
of initial exposure to risk factors is important in determining the 
relation between risk factors and outcomes; these studies employ 
survival analysis. SR, systematic review; RCT, randomized clinical 
trial; CT, clinical trial
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such as endophthalmitis or residual refractive 
errors. (IV), (consensus, C11)
13. In bilateral cataract cases, it is recommended to 
perform surgery in separate sessions in order to 
achieve better binocular vision.[46‑50] (I), (R5.2)
14. Because of the chance of endophthalmitis and 
bilateral toxic anterior segment syndrome (TASS), 
simultaneous surgery on both eyes is  not 
recommended.[51‑53] (III), (C12)
15. In one‑eyed cataract patients, surgery is recommended 
if the advantages of performing the surgery are higher 
than its side effects.[54,55] (III), (C10)
16. Based on scientific evidence, performing cataract 
surgery might reduce intraocular pressure in patients 
who also have closed angle glaucoma.[56‑63] (II), (A2 6)
17. If there is a chance of blindness due to increased 
intraocular pressure after cataract surgery and 
glaucoma surgery, simultaneous surgery is 
recommended. (IV), (consensus, C18)
18. Cataract  surgery is  indicated in  pat ients 
with phacomorphic glaucoma, lens‑induced 
uvei t i s ,  and poster ior  segment  d iseases , 
if lens opacity limits fundus examination or 
treatment. (IV), (consensus, C5).
S u r g i c a l  T r e a t m e n t s / P r e o p e r a t i v e /
Assessment/Eye Assessment
19. It is recommended for all cataract surgeons to answer 
the following questions prior to surgery in order to 
prevent or reduce some risk factors:[64]
Is the cataract the main cause of vision loss?
Is there any other eye disease like glaucoma that 
might worsen because of cataract surgery?
Is there any eye disease that might complicate the 
surgical process? (I), (C7)
20. The surgeon should refer the patients to facilities 
with more expertise if the surgery seems to be very 
complicated, has a high risk of complications, or the 
surgeon does not have enough experience.[65] (II), (C8)
21. α‑blockers (tamsulosin) should be discontinued 
before surgery because of the high risk of 
floppy iris syndrome (FIS) and other serious 
complications.[66‑71] (I), (A2, 5)
22. Due to the absence of serious vision related 
side effects, discontinuation of anti‑coagulant 
medications (except for Warfarin and Clopidogrel) 
is not recommended.[72‑75] (I), (C26, R7‑5‑1)
23. If a surgeon encounters a higher incidence of 
endophthalmitis compared to what has been reported 
in the literature, it is recommended to search for the 
source of this complication by taking serial microbial 
cultures from personnel, surgery room, and devices 
as well as controlling the sterilization process. Also 
preps of eyelashes with 10% betadine and preps of 
the cul‑de‑sac and conjunctiva with 5% betadine are 
recommended. (IV), (consensus, C57 and external 
consensus)
24. It is recommended that a form, including the eye 
undergoing surgery, IOL power, medications used 
by the patients, previous diseases, etc., be prepared 
at all eye surgical centers and filled out immediately 
before surgery by the surgeon or the operating 
room staff. It is also recommended that patient 
education brochures be given to all patients or their 
accompanying person after surgery (including 
information about post‑surgical pain, introduction 
of drugs, time for post‑operative visits, etc.).[76‑81] (II), 
(A2 11).
S u r g i c a l  T r e a t m e n t s / P r e o p e r a t i v e /
Assessment/Lab Assessment
25. Performing general  medical  preoperat ive 
examinations, even when using local anesthesia, is 
recommended.[82,83] (I), (R4) and (IV), (external peer 
review).
S u r g i c a l  T r e a t m e n t s / P r e o p e r a t i v e /
Assessment/IOL Assessment
26. It is recommended to repeat A‑scan biometry in the 
following circumstances:[84,85]
• Axial length more than 26mm or less than 21mm
• Keratometry more than 47 diopters or less than 
41 diopters
• Astigmatism more than 2.5D
• Axial length difference more than 0.7 between the 
two eyes
• Keratometry difference of more than 0.9 between 
the two eyes (III), (R 8‑7‑4)
27. It is recommended that optical (laser interferometry) 
biometry or utrasonography with immersion 
technique be used to find the exact axial length. 
Both methods are superior to contact method.[86,87] 
(I), (C31)
28. In eyes with abnormal size, the surgeon should use 
Holladay 2 or Haigis formulas to achieve the best 
post‑operative refractive outcomes. (IV) (consensus, 
C33)
29. To achieve the best postoperative refractive results, 
it is recommended to calculate the lens power using 
Table 8. Abbreviations of the reference guidelines
A1: American Academy of Ophthalmology: Cataract in the 
adult eye. Preferred practice pattern. (2006)
A2: American Academy of Ophthalmology: Cataract in the 
Adult Eye. Preferred practice pattern (2011)
C: Canadian Ophthalmological Society evidence‑based 
clinical practice guidelines for cataract surgery in the adult 
eye (2008)
R: The Royal College of Ophthalmologists: Cataract 
Surgery Guidelines (2010)
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the new generation formulas (Hoffer Q, SRK/T, 
Holladay).[88] (III), (C32)
30. Surgeons should optimize their IOL A‑constant based 
on their postoperative refractive results and consider 
it in IOL power calculation. (IV), (consensus, C34)
31. The effect of A‑constant optimization on IOL power 
prediction is more pronounced when using the 
modern IOL power calculation formulas. In some 
cases, the percentage of eyes with acceptable refractive 
range after surgery (Target refraction ± 1D) can be 
increased by 20% when A‑constant optimization is 
applied. (IV), (consensus, R 8‑7‑5)
32. The A‑constant provided by the manufacturer 
which is calculated by contact sonography is 
different from optical optimized A‑constant. To 
improve the A‑constant of newer intraocular lenses 
in optical biometry, ULIB online website should be 
utilized. (IV) (consensus, R8‑7‑1)
33. Patients with a history of refractive surgery should be 
informed about the possibility of errors in IOL power 
calculation and postoperative refraction even when 
utilizing adjustments. (IV), (consensus, C38)
34. In patients who have a history of keratorefractive 
surgery, surgeons should be aware of the possibility 
of unusual postoperative refractive results and should 
calculate the real corneal refractive power using 
adjusted formulas, utilizing patient preoperative 
findings, or direct calculation of the central corneal 
power using SimKs or Scheimpflug methods. It is 
ideal to apply several methods for calculating the 
IOL power. (IV), (consensus, C36)
35. It is recommended that the past medical and ocular 
history, including keratometry and biometry results, 
of all patients undergoing keratorefractive surgery be 
kept by the treatment center.[89] (II), C37)
36. It is recommended to use IOLs with sharp 
angles to lessen the chance of posterior capsule 
opacity.[90‑109] (I), (R10, C62)
37. The use of anterior aspheric IOLs is recommended 
to achieve better contrast sensitivity and visual 
performance particularly during the night. It 
should be noted that in conditions like zonular 
rupture and astigmatism, which increase the 
chance of IOL decentration, or after hyperopic 
corneal refractive surgery, spherical IOLs should be 
implanted.[110‑112] (I), (C42, R 9‑7‑4)
38. In the process of using multifocal or accommodative 
IOLs which correct different degrees of presbyopia, 
careful patient selection and consultation, informing 
the patient about the results, and utilizing necessary 
preoperative examinations are vital. (IV), (consensus, 
C44)
39. It is recommended that multifocal and adjustable 
lenses be used based on patient needs and desires, and 
after giving the patient complete information about 
the advantages and disadvantages of such lenses, 
including glare/haloes, posterior capsular opacity 
and reduction of contrast sensitivity.[113‑115] (I), R 9‑7‑1)
40. To use toric IOLs in patients with regular preoperative 
corneal astigmatism, accurate preoperative 
calculations, correct marking of the steep axis, 
and implanting the IOL in correct axis should be 
considered to eliminate undesirable surgical induced 
astigmatism. (IV), (consensus, C43)
41. Visual outcomes after cataract surgery and 
implantation of UV filter IOLs and blue filter IOLs 
are comparable.[116,117] (I), (New) ‑ (IV), (Internal and 
external consensus)
42. When the PCIOL is placed in the ciliary sulcus, 
decreasing the power by 0 to 1.5 diopters should be 
considered. (IV), (consensus, C35).
Surgical Treatments/Preoperative/Risk 
Factors of Cataract Surgery
43. It is preferable that the waiting time for cataract surgery 
be less than 2 to 3 months to avoid the chance of visual 
deterioration and possible accidents.[118,119] (I), (R 4)
44. Patients with cataracts and at danger of the 
consequences of reduced vision, namely falls, 
fractures or accidents, should undergo surgical 
correction as soon as possible.[120‑125] (I), (C6)
45. It is recommended that all patients with cataracts 
be informed about the chance of PCO before 
surgery.[90‑109] (III), (R10)
46. It is recommended that the chance of aggravation 
of diabetic retinopathy be discussed with patients 
with diabetes and lens opacity who are undergoing 
cataract surgery.[126,127] (III), (C21)
47. If the surgeon finds a serious condition in the 
pre‑surgical examinations like tractional retinal 
detachment, it is recommended that consultation 
for performing combined vitrectomy and cataract 
surgery be considered.[128] (III), (C20)
48. Treatment of proliferative diabetic retinopathy (PDR) 
and clinically significant macular edema (CSME) 
should be performed before cataract surgery, if 
possible. (IV), (consensus, C20)
49. It is recommended that the risk of retinal detachment 
be discussed with high‑risk patients (patients with 
posterior capsule tear and consequent anterior 
vitrectomy, age less than 60 years, male sex, and high 
myopia). They should also be informed of the warning 
signs and symptoms of retinal detachment to facilitate 
early diagnosis and treatment.[129‑131] (I), (C64)
50. In patients with Fuchs’ dystrophy and cataract, if the 
chance of corneal decompensation is considerable, 
combined cataract and corneal transplantation could 
be considered. (IV), (consensus, C17)
51. Anterior chamber depth less than 2.5mm in patients 
with pseudoexfoliation (PEX) increases the chance of 
complications during the cataract surgery.
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Accompanying recommendation: It is recommended 
that cataract surgery in these patients be performed 
by a more experienced surgeon in order to decrease 
the risk of complications.[132] (II), (C23)
52. Cataract surgery after trabeculectomy (TX) increases 
the chances of TX failure. A shorter time interval 
between the two surgeries increases the risk of this 
failure[133] (I), (New) ‑ (IV), (Internal and external 
consensus)
53. It is recommended that patients with age‑related 
macular degeneration (ARMD) undergo cataract 
surgery only if there is a chance for improved vision. 
Informing the patient about the chance of worsening 
of macular degeneration following cataract surgery 
is necessary.[134‑137] (I) (C 15).
Surgical Treatments/Intraoperative
54. Treatment of blepharitis before surgery and 
also prep of the eyelashes with 10% betadine 
and prep of the cul‑de‑sac and conjunctiva 
with 5% betadine immediately before surgery 
is recommended to decrease the chance of 
endophthalmitis.[138‑143] (II), (C55)
55. The choice of local anesthesia for cataract surgery 
is made based on the patient and surgeon’s 
preference.[144‑149] (I) (R 7‑2‑2)
56. Phacoemulsification using a small incision is the 
preferred method of cataract surgery compared to 
extracapsular cataract extraction since it causes less 
astigmatism, achieves fast and better visual outcomes, 
and has fewer complications.[150‑152] (I) (C45)
57. Smaller incisions (3.2 mm) during cataract surgery 
are recommended due to less astigmatism and less 
short‑term changes in the cornea.[153,154] (I), (C46)
58. Implantation of foldable IOLs is preferable to rigid 
IOLs since they require smaller incisions, cause less 
astigmatism, provide better visual acuity, and cause 
less postoperative inflammation.[155] (I) (C40)
59. Staining of the anterior capsule is recommended 
in mature cataracts, white cataracts, complicated 
cataracts and in children.[156] (I) (C50)
60. Smaller capsulorhexis (4.5mm to 5mm) which can 
completely cover the margin of the IOL optic are 
preferable to larger ones since they decrease the 
chance of PCO.[157] (I), (C47)
61. It is recommended that hydrodissection and 
hydrodelineation be performed routinely to reduce 
tension on the zonulae, facilitate cortical removal, 
and reduce the chance of PCO.[158] (I) (C48)
62. The surgeon should ask patients about the history 
of using alpha adrenergic blocker medications 
(e.g. Tamsulosin), which cause intraoperative floppy 
iris syndrome. If there is a positive history, atropine 
drops and intraocular epinephrine should be used 
both before and during surgery. The surgeon should 
also use less fluid circulation and more viscoelastic 
materials as well as iris retractors and pupil rings to 
reduce the chance of floppy iris syndrome. Due to 
chance of bleeding, iris sphincterotomy should be 
avoided.[159‑164] (I), (A25), (IV), (consensus C53)
63. To reduce surgical complications, a small pupil 
should be enlarged appropriately. To achieve 
this goal, different methods can be used based 
on surgeon’s experience and methods with less 
trauma. Usual methods include stretching hooks, 
rings, and pupil retractors, and using ophthalmic 
visco‑surgical devices (OVDs).[165] (IV) (consensus, 
C52)
64. Performing phacoemulsification with a torsional 
probe is preferred to conventional longitudinal 
probes since there is less chance of corneal 
trauma.[166‑171] (I), (New) ‑ (IV), (Internal and external 
consensus)
65. In patients with local or general zonular weakness, 
applying capsular tension rings is recommended 
to achieve better  control  during surgery, 
reduce complications, and provide better IOL 
centration.[172] (I), (51)
66. Considering the reduced incidence of side effects 
of using injectors (as compared to forceps) for 
implanting IOLs such as less wound damage, less 
IOLs damage, and a lower chance of endophthalmitis, 
it is recommended to implant the IOL using its special 
injector.[173] (III), (C41)
67. In the absence of inadequate capsular bag support, the 
surgeon should determine a suitable IOL (considering 
lens power and material) to be implanted in the ciliary 
sulcus.[174‑178] (III), (A2, 10)
67‑1: IOLs designed for in‑the‑bag implantation 
should not be implanted in the ci l iary 
sulcus.[174‑178] (III) (A2, 10‑1)
67‑2: When placing an IOL in the ciliary sulcus, 
the power should be reduced as compared to 
in‑the‑bag implanted IOLs.[174‑178] (A2, 10‑2)
67‑3‑ Implantation of multifocal and aspheric IOLs in 
the ciliary sulcus are not recommended.[174‑178] (III), 
(A2 10‑3)
68. In case of posterior capsular rupture and inadequate 
capsular support for in‑ the‑bag IOL implantation, 
ACIOLs, scleral fixation PCIOLs, or iris fixation IOLs 
may be used.[179] (III), (C39)
69‑ 1‑ Intracameral antibiotic injections are not recommended 
to reduce the chance of endophthalmitis due to the 
toxic effects and likelihood of reduction in corneal 
endothelial cells.[180‑187] (III), (A28) ‑ (IV), (Internal and 
external consensus)
69‑2‑ Subconjunctival antibiotic injection may 
be recommended to reduce the chance of 
postoperative endophthalmitis with weak level of 
evidence.[180‑187] (III), (A28).
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Surgica l  Treatments /Postoperat ive /
Complications
70. Use of high frequency postoperative antibiotics 
is  recommended to reduce the chance of 
endophthalmitis.[180‑187] (III), (A2 8) ‑ (IV), (Internal 
and external consensus)
71. To treat postoperative cystoid macular edema (CME), 
topical non‑steroidal anti‑inflammatory drugs (NSAIDs) 
such as ketoralac 0.5 percent are recommended as the 
first step of therapy.[188,189] (I), (R4)  ‑ (IV), (Internal and 
external consensus)
72. Before performing Nd: YAG laser capsulotomy for 
treatment of PCO, patients at high risk of retinal 
detachment (RD) such as posterior capsule rupture 
in the other eye, axial length more than 23 mm, and 
male sex, should be informed of the possibility of RD 
following laser capsulotomy.[190] (II), (C63)
73. Postoperative intraocular inflammation is considered 
as a risk factor for corneal, trabecular and retinal 
complications, therefore the use of steroids or NSAIDs 
immediately after surgery to reduce inflammation is 
recommended. (IV), (consensus, C54)
74. Because of the common use of antibiotics, resistance 
to several antibacterial agents such as penicillin and 
fluoroquinolones for treatment of postoperative 
staphylococcal endophthalmitis is observed. 
Ophthalmologists should be aware of this problem 
and consider it when prescribing post‑operative 
antibiotics (resistance to ciprofloxacin has also been 
reported in several reports).[191‑197] (III), (A27)
75. Although toxic anterior segment syndrome (TASS) 
is rare, ophthalmologists should be aware of 
i ts  predisposing factors such as posterior 
capsule rupture, vitreous loss, and potential 
complications.[198,199] (III), (A29)
76. It is recommended to consider complications 
like dysphotopsia and lens capsule opacity when 
choosing the IOLs.[200] (I), (C65).
Surgical Treatments/Postoperative/Follow‑up
77. All patients undergoing phacoemulsification surgery 
should be aware of the postoperative examination 
schedule and possible side effects of the surgery. It 
is recommended to perform the first postoperative 
examination up to 24 hours after the surgery. The 
exact timing of other postoperative visits depends on 
the circumstances of the operation and the method 
used, complications, and surgeon and patient 
preference. (IV) (consensus, C59‑60) ‑ (IV), (Internal 
and external consensus)
78. In high risk conditions like monocular patients, 
glaucomatous eyes or glaucoma suspects and surgical 
complications, the first visit should be performed by 
24 hours after surgery and more frequent follow‑up 
examinations are needed. Patients should be 
instructed to inform their ophthalmologists as soon 
as possible in case of severe reduction of vision, 
increased pain, redness, or inflammation around 
the eye as these might be signs of endophthalmitis.
(IV) (consensus, C61)
79. Final evaluation of refractive power should be 
performed 2 weeks postoperatively in patients 
with small corneal incisions (under 3.5mm) and 
after 6 weeks in patients with larger incisions or 
extracapsular operations. More postoperative 
examinations during this period, or even after it, 
are recommended based on special circumstances of 
the surgery, postoperative complications, the need 
for removing corneal sutures, and also evaluating 
intraocular pressure (IV), (consensus, C61).
80. To evaluate patient satisfaction, visual assessment using 
a high contrast Snellen chart is not enough. Standard 
questionnaires like the VF14 will provide greater 
insight into patient satisfaction. (IV), (consensus, 
R12‑6) ‑ (IV), (Internal and external consensus).
DISCUSSION
The current CPG for treatment of cataracts in adult Iranian 
patients was customized based on the standard method 
suggested by the Iranian Ministry of Health and Medical 
Education at the knowledge management unit (KMU) 
of Shahid Beheshti University of Medical Sciences. 
This guideline includes 80 recommendations covering 
preoperative, intraoperative, and postoperative aspects 
related to adult cataract management. In the process 
of preparing the guidelines, preliminary consensus 
was not achieved in 15 out of 80 recommendations. 
These 15 recommendations were further discussed in 
internal panels, and 6 primary recommendations were 
reapproved, 8 recommendations were modified, and one 
recommendation was omitted. The changes were applied 
to 8 recommendations as follows: Recommendation 
number 5, which initially recommended that “the 
use of steroid drugs, amitriptyline, statins, and 
potassium‑sparing diuretics increase the risk of cataract 
or its progression, and the use of aspirin and thiazides 
do not increase this chance”, was modified to “The use 
of steroids, amitriptyline, statins, anti‑diabetes pills, 
insulin, and potassium‑sparing diuretics increase the 
risk of cataracts and cause faster progression of the 
condition, but aspirin and thiazides do not have a role 
in this respect. Discontinuation of cataract‑causing drugs 
may be recommended by physicians, if possible.”
Recommendation number 23, which stated, “If a 
surgeon encounters a higher incidence of endophthalmitis 
compared to what has been reported in the literature or in 
instances that the risk of postoperative endophthalmitis 
is higher due to complicated surgery, the postoperative 
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injection of intracameral or subconjunctival antibiotics 
should be considered.” was changed to “If a surgeon 
encounters a higher incidence of endophthalmitis 
compared to what has been reported in the literature, 
it is recommended to search for the source of this 
complication by taking serial microbial cultures from 
personnel, surgery room, and its devices as well as 
controlling the sterilization process. Also, preparation 
of eyelashes with 10% betadine and preparation of 
the cul‑de‑sac and conjunctiva with 5% Betadine is 
recommended.”
Recommendation number 25 initially stated, 
“Considering the available data, preoperative 
examination does not increase the safety of cataract 
surgery. If the patient does not suffer from any special 
condition or diseases, performing routine preoperative 
exams are not recommended.” Considering the condition 
among Iranian patients and the fact that they might 
not have any previous systemic evaluation, after panel 
discussion this was changed to: “Performing general 
medical preoperative examinations, even when using 
local anesthesia, is recommended.”
Recommendation number 39 which stated that “The 
use of multifocal or adjustable lenses should be based 
on the necessity and the desire of the patient and after 
giving the patient a good understanding of advantages 
and disadvantages (glare/haloes, PCO)”, was changed 
to “It is recommended that multifocal and adjustable 
lenses be used based on patient needs and desires, and 
after giving the patient complete information about the 
advantages and disadvantages of such lenses, including 
glare/haloes, posterior capsular opacity and reduction 
of contrast sensitivity)."
The first version of recommendation number 
50 stated: “In cataract patients with Fuchs’ dystrophy, if 
the surgeon gives a chance of corneal decompression, the 
cataract and corneal surgeries are better to be combined.” 
After panel discussion, the term “is better” was changed 
to term “could", and the final recommendation was:” In 
patients with Fuchs’ dystrophy and cataract, if the chance 
of corneal decompensation is considerable, combined 
cataract and corneal transplantation can be considered.”
The initial statement for recommendation number 
64 was “Performing phacoemulsification using a 
torsional probe is recommended compared to the use 
of conventional longitudinal probes since there is less 
chance of corneal trauma.” This recommendation was 
finalized in the discussion panel with a minor change 
as follows: “Performing phacoemulsification with a 
torsional probe is preferred to conventional longitudinal 
probes since there is less chance of corneal trauma.”
Two recommendations which were about antibiotic 
usage during surgery and postoperatively were 
discussed in the panel and the primary recommendation 
of “inject proper antibiotic in the anterior chamber to 
reduce the chance of endophthalmitis” was rejected by 
panel members, and intracameral prophylaxis antibiotic 
was not recommended as mentioned in recommendation 
69‑1.
Finally, before the panel discussion, recommendation 
number 71 suggested the use of NSAIDS for treatment 
of postoperative acute cystoid macular edema was 
not recommended, but it was changed to, “To treat 
postoperative cystoid macular edema (CME), topical 
non‑steroidal anti‑inflammatory drugs (NSAIDs) such 
as ketoralac 0.5 percent are recommended as the first 
step of therapy.”
At the end of the discussion panel, all final 
recommendations were edited and finalized as final 
recommendations.
This guideline, as compared to the cited CPGs 
which were used, has more detailed recommendations 
considering different aspects of cataract surgery, including 
important pre‑, intra‑, and postoperative aspects of the 
surgery. For example, the Canadian Ophthalmological 
Society evidence‑based clinical practice guidelines for 
cataract surgery in the adult eye (2008) contains 65 
recommendations, but the present guideline consists of 
80 recommendations. On the other hand, this customized 
guideline has the benefit of considering clinical advantages 
and practicality among Iranian patients, so its use among 
the Iranian population should be more effective.
In conclusion, the current clinical practice guideline 
for adult cataract management was customized for an 
Iranian adult population at KMU at the Ophthalmic 
Research Center, Shahid Beheshti University of 
Medical Sciences as suggested by the Standardization 
and CPG Development Office, Deputy of Curative 
Affairs, and the Iranian Ministry of Health and Medical 
Education. Therefore, its recommendations can be used 
to standardize different aspects in the management of 
adult patients with cataracts.
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